Merck: Access to Health

In collaboration with key stakeholders, we work to ensure our science advances health care, and our products are accessible and affordable to those in need.

Videos from Client

Content from this campaign

Health & Healthcare

Vaccines: Our History, Our Legacy
This was the desperate radio telegram in January 1925 from Dr. Curtis Welch in Nome, Alaska, to all the major Alaska towns, to territorial Governor Scott Bone in Juneau

Health & Healthcare

Merck and Ridgeback Announce Supply Agreement With UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced the signing of a long-term supply agreement with the United Nations Children’s Fund (UNICEF) to facilitate broad global access for molnupiravir, an investigational

Philanthropy & Cause Initiatives

Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities
Merck, known as MSD outside the United States and Canada, announced an additional $150 million commitment through Merck for Mothers to further advance the initiative’s mission of helping create a world where no woman has to die giving life.

Responsible Business & Employee Engagement

Showing Our Gratitude: Addressing COVID-19 Takes a Global Effort
Taking on COVID-19 isn’t just a team effort — it’s also a global one. Here at Merck, we’re grateful to all the people who have worked hard to keep us safe, along with everyone around the world helping to combat the pandemic.

Health & Healthcare

Merck and Ridgeback's Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19
Merck and Ridgeback Biotherapeutics announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for molnupiravir, an investigational oral antiviral (MK-4482, EIDD-2801).

Health & Healthcare

Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine
Merck and Ridgeback Biotherapeutics announced the New England Journal of Medicine has published findings from the Phase 3 MOVe-OUT trial evaluating molnupiravir, an investigational oral antiviral COVID-19 medicine.

Philanthropy & Cause Initiatives

The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries
The Medicines Patent Pool (MPP) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the signing of a voluntary licensing agreement to facilitate affordable global access for molnupiravir.

Health & Healthcare

Merck Announces Alliance for Equity in Cancer Care
To help address persistent disparities across the cancer care continuum – from diagnosis to survivorship – and improve patient outcomes among adult underserved populations, the Merck Foundation announces a new U.S. initiative, the Merck Alliance for Equity in Cancer Care

Health & Healthcare

6 Global Trends Critical to Patients During the COVID-19 Pandemic
Merck recently hosted an expert panel of patient advocacy leaders from around the world to discuss shifts in health care and the impact on patients during the next phases of the pandemic. Special Report: COVID-19 and the Patient Perspective summarizes the panel conversation.

Health & Healthcare

Fighting for Health Equity From Inside the Health Care Industry
For as long as she can remember, Carmen Villar wanted a purpose-driven career that allowed her to give back to the community.

More from Merck & Co., Inc.

Merck: Ethics & Values

Through our unwavering commitment to transparency, we earn the trust and confidence of our stakeholders.

Merck: Access to Health

In collaboration with key stakeholders, we work to ensure our science advances health care, and our products are accessible and affordable to those in...

Merck: Employees

We recognize that our ability to excel depends on the integrity, knowledge, imagination, skill, diversity and wellbeing of our employees.

Merck: Environmental Sustainability

We consider the impacts of our operations and strive to operate our business sustainably to support the health of our planet and its people.